Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 5/20 | 0.51 |
| ▸ | BRAF known ✓ | P15056 | 3/20 | 0.51 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.51 |
| ▸ | BCR known ✓ | P11274 | 1/20 | 0.51 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.51 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.51 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 8/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.51 |
| ▸ | SYK | P43405 | 4/20 | 0.51 |
| ▸ | RAF1 | P04049 | 3/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.51 |
| ▸ | HCK | P08631 | 2/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | ACOX3 | O15254 | 1/20 | 0.51 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.51 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030941 | 0.97 | MAPK14 (0.53) | SRCMAPK14ABL1SYKBRAF | |
| SCHEMBL2031868 | 0.92 | SRC (0.49) | SRCMAPK14ABL1SYKBRAF | |
| SCHEMBL5057180 | 0.92 | SRC (0.52) | SRCMAPK14ABL1SYKBRAF | |
| SCHEMBL2029518 | 0.89 | MAPK14 (0.55) | SRCMAPK14ABL1SYKBRAF | |
| SCHEMBL5057178 | 0.87 | MAPK14 (0.54) | SRCMAPK14ABL1SYKBRAF | |
| SCHEMBL2027424 | 0.87 | ABL1 (0.54) | SRCMAPK14ABL1SYKBRAF | |
| SCHEMBL30681051 | 0.87 | ABL1 (0.66) | SRCMAPK14ABL1SYKBRAF | |
| SCHEMBL2030992 | 0.87 | ABL1 (0.66) | SRCMAPK14ABL1SYKBRAF | |
| Hydrochloric Acid SCHEMBL2022848 | 0.86 | ABL1 (0.65) | SRCMAPK14ABL1SYKBRAF | |
| SCHEMBL12080470 | 0.86 | MAPK14 (0.56) | SRCMAPK14ABL1SYKBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2073811-B1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS LLC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8586565-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-09-06 | — | — | US | disclosed |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | disclosed |
| US-7790756-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | ABL1, MCL1, ABL2 | ABL1 1/4885BRAF 5/4885KIT 847/4885 |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | MYLK3, MYLK, CDK3 | ABL1 81/4885BRAF 115/4885KIT 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.